MicroRNA silencing improves the tumor specificity of adenoviral transgene expression.

Cancer Gene Therapy
P B CardR D Gerard

Abstract

Adenoviral technology has been thoroughly evaluated for delivering genetic material to tumor tissue and the surrounding microenvironment. Almost any gene can be cloned into an adenovirus (Ad) vector, which when combined with strong, constitutively active promoters permit up to a million-fold amplification of the transgene in a single adenoviral particle, thus facilitating their use in cancer therapy and imaging. However, widespread infection of the liver and other non-targeted tissues by Ad vectors is a substantial problem that often results in significant liver inflammation and hepatotoxicity at doses required to achieve efficient tumor transduction. miR-122 is a highly expressed liver-specific microRNA (miRNA) that provides a unique opportunity for downregulating adenoviral transgene expression in liver tissue. The binding of endogenous miRNAs to complementary miRNA-targeting elements (miRTs) incorporated into the 3' untranslated region of adenoviral transgenes interferes with message stability and/or protein translation, and miRT elements against miR-122 (miRT-122) can selectively reduce adenoviral transgene expression in the liver. Previous studies using miR-122-based regulation, with and without other types of transcriptio...Continue Reading

References

Apr 1, 1996·Current Opinion in Lipidology·R D Gerard, L Chan
Jan 31, 1998·Cardiovascular Research·R D Gerard, D Collen
Feb 13, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·N TaoS E Fawell
May 15, 2002·Current Biology : CB·Mariana Lagos-QuintanaThomas Tuschl
May 21, 2003·Gene Therapy·Q Liu, D A Muruve
Jun 2, 2005·Nature Reviews. Cancer·Dario Neri, Roy Bicknell
Aug 23, 2006·Journal of Cellular Biochemistry·Huban KutayKalpana Ghoshal
Oct 31, 2006·Oncogene·M S HaydenS Ghosh
Feb 19, 2008·Investigative Ophthalmology & Visual Science·Elhadji M DioumJoseph A Garcia
Feb 23, 2008·Journal of Hepatology·Muriel GirardAlexandra Henrion-Caude
Jul 31, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Takayuki SuzukiHiroyuki Mizuguchi
Aug 28, 2009·Journal of Cellular Biochemistry·Anne K ZaissHarvey R Herschman
Sep 19, 2009·Nature Reviews. Genetics·Carlo M Croce
Oct 8, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chunxiao WuShu Wang
Feb 9, 2010·Cancer Gene Therapy·R T HoggR D Gerard
Jun 11, 2010·Annual Review of Biochemistry·Marc Robert FabianWitold Filipowicz
Dec 25, 2010·Cancer Gene Therapy·R T HoggR D Gerard
Oct 1, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Takayuki SuzukiHiroyuki Mizuguchi

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
PCR

Software Mentioned

SigmaStat

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.